Starting on
SCEMBLIX
In newly diagnosed
Ph+ CML in chronic phase
Patient portrayal
More people achieved a major molecular response (MMR) with SCEMBLIX than with the most commonly used TKIs.*
TKI, tyrosine kinase inhibitor.
*SCEMBLIX was studied vs GLEEVEC® (imatinib), TASIGNA® (nilotinib), Sprycel® (dasatinib), and Bosulif® (bosutinib).
SCEMBLIX vs the TKIs doctors use most
In a clinical study of adult patients with newly diagnosed Ph+ CML in chronic phase, nearly 7 out of 10 patients (68%, or 136 of 201) achieved MMR with SCEMBLIX at nearly 1 year (48 weeks) vs nearly 5 out of 10 patients (49%, or 100 of 204) who achieved MMR with one of the following TKIs: GLEEVEC, TASIGNA, Sprycel, and Bosulif.†
†Sprycel is a registered trademark of Bristol-Myers Squibb Company. Bosulif is a registered trademark of Pfizer Inc.
SCEMBLIX vs GLEEVEC
In a clinical study of adult patients with newly diagnosed Ph+ CML in chronic phase, nearly 7 out of 10 patients (69%, or 70 of 101) achieved MMR with SCEMBLIX at nearly 1 year (48 weeks) vs 4 out of 10 patients (40%, or 41 of 102) with GLEEVEC.
In this clinical study, the most common side effect reported (≥20%) with SCEMBLIX was pain in the muscles, bones, or joints.
Everyone responds differently to treatment. That’s why it’s important to discuss the potential side effects of each treatment you and your doctor are considering to treat Ph+ CML in chronic phase.
What is MMR?
Achieving a major molecular response, or MMR, is one of the treatment milestones in Ph+ CML in chronic phase. Ask your doctor to explain this goal and find out if MMR may be within your reach if you start treatment with SCEMBLIX.
Patients who had to stop treatment at nearly 1 year (48 weeks) due to side effects
In a clinical study of adult patients with newly diagnosed Ph+ CML in chronic phase, 4.5% of patients (9 of 200) had to stop taking SCEMBLIX due to side effects vs 10.4% of patients (21 of 201) with one of the following commonly used TKIs: GLEEVEC, TASIGNA, Sprycel, or Bosulif.
Ask your doctor about SCEMBLIX
Before you start on treatment for Ph+ CML in chronic phase, ask your doctor about the potential benefits and risks of different medications.
Questions to ask your doctor about SCEMBLIX as your first medication for Ph+ CML in chronic phase:
How is SCEMBLIX different from other medications that treat Ph+ CML in chronic phase?
How quickly should I expect to see results with SCEMBLIX?
What are some side effects that I might experience with SCEMBLIX?
How will I know if SCEMBLIX is working?
What are some important treatment milestones?
Common side effects of SCEMBLIX
The most common side effects of SCEMBLIX include:
muscle, bone, or joint pain
rash
tiredness
nose, throat, or sinus (upper respiratory tract) infections
headache
stomach-area (abdominal) pain
diarrhea
decreased white blood cell counts, platelet counts, and red blood cell counts
decreased blood calcium corrected levels
increased blood pancreas enzyme (lipase and amylase) levels
increased blood fat (cholesterol and triglycerides) levels
increased blood uric acid levels
increased blood liver enzyme levels
increased blood alkaline phosphatase levels
increased blood creatine kinase levels
Your doctor may change your dose, temporarily stop, or permanently stop treatment with SCEMBLIX if you have certain side effects.
SCEMBLIX may cause fertility problems in females. This may affect your ability to have a child. Talk to your doctor if this is a concern for you.
Be sure to review information about the serious and most common side effects of SCEMBLIX. Learn more
